A phase II study of the efficacy, safety and immunogenicity of OncoVexGM-CSF in patients with stage IIIc and stage IV malignant melanoma.

Trial Profile

A phase II study of the efficacy, safety and immunogenicity of OncoVexGM-CSF in patients with stage IIIc and stage IV malignant melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors BioVex
  • Most Recent Events

    • 03 Nov 2009 Results reported online in the Journal of Clinical Oncology.
    • 16 May 2008 Interim results reported in a BioVex media release.
    • 16 May 2008 The abstract describing interim results is now available at www.asco.org
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top